# Pyxis Oncology, Inc. (PYXS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $105M  
**Price:** $1.69 (+1.20%)

> Pyxis Oncology Inc. is a biopharmaceutical company dedicated to developing an innovative portfolio of next-generation medicines targeting cancer. The primary focus of the company lies in harnessing proprietary technologies to advance novel antibody-based therapeutics. By emphasizing precision medicine, Pyxis Oncology aims to create therapies that improve the standard of care for cancer patients, addressing specific unmet medical needs. The company operates in the highly specialized pharmaceutical and biotechnology sectors, where breakthrough treatments can significantly impact patient outcomes. Its ongoing research and development efforts place Pyxis Oncology among the trailblazers in the medical industry, contributing to the expansion of targeted therapy options. With its dedication to pioneering drug discovery, Pyxis Oncology plays a crucial role in the evolving landscape of cancer treatment, which is a critical component of the broader healthcare and life sciences markets. The company's mission to transform the oncology therapeutic field underscores its importance in the pursuit of comprehensive cancer care solutions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $14M | $11M | -$84M | -$80M | $-1.28 |
| 2024 | $16M | $16M | -$89M | -$77M | $-1.32 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $92M | $38M | $53M | $15M | — |
| 2024 | $157M | $36M | $121M | $19M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$64M | $9,000 | -$64M |
| 2024 | -$58M | $237,000 | -$58M |
| 2023 | -$71M | $7M | -$77M |
| 2022 | -$89M | $6M | -$96M |
| 2021 | -$35M | $540,000 | -$36M |
| 2020 | -$10M | $1M | -$12M |

Source: [CompaniesByCap](https://companiesbycap.com/company/PYXS)